Clinical Trials Logo
  1. Home
  2. Metastatic Colon Cancer
  3. NCT03764137
  4. Details
NCT03764137 Clinical Trial

Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer

Metastatic Colon Cancer Clinical Trial

— Panitumumab  

Official title:
Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT03764137
Other study ID # 300002089
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received
Last updated
Start date March 14, 2019
Est. completion date January 2026

Study information
Verified date October 2022
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date January 2026
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Be at least 19 years of age. - Diagnosis of colon cancer - Scheduled to undergo surgical resection Exclusion Criteria: - Inability to provide informed consent - Pregnancy - Inability to lie still for the imaging study - Weight over 350 lbs., due to the scanner bore size - Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos) - Inability to receive Omnipaque (iohexol) iodinated contrast - Inability to receive glucagon - Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent - Allergy to contrast imaging agents - Finding or suspicion of distant metastases on CT

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• [89Zr]Panitumumab PET-MRI
All patients entered into the study will have [89Zr]Panitumumab-PET/MRI imaging.

Locations
Country Name City State
United States UAB Advanced Imaging Facility Birmingham Alabama

Sponsors (1)
Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Image Quality Diagnostic image quality of [89Zr]Panitumumab PET imaging in patients with newly diagnosed colon cancer with nodal involvement. Standardized Uptake Values (SUVs) will be measured. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04186117 - Development of Clinical and Biological Database in Colorectal Cancer N/A
Completed NCT05468892 - Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial Phase 2
Recruiting NCT02291744 - A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients Phase 2
Active, not recruiting NCT00986661 - A Study to Assess PV-10 Chemoablation of Cancer of the Liver Phase 1
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT05983367 - A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer Phase 2
Recruiting NCT03730558 - ZETA : Prospective Observational Study
Recruiting NCT06180460 - CALM: Managing Distress in Malignant Brain Cancer N/A
Active, not recruiting NCT03251378 - A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer Phase 1
Recruiting NCT04737213 - SGM-101 in Colorectal Lung Metastases Phase 2
Recruiting NCT05714124 - Liver Embolization Approaches for Tumor Management
Recruiting NCT05396807 - REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients N/A
Active, not recruiting NCT02724202 - Curcumin in Combination With 5FU for Colon Cancer Early Phase 1
Recruiting NCT05848739 - A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06202183 - Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial N/A
Withdrawn NCT01936961 - Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors N/A
Not yet recruiting NCT06358677 - Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer Phase 2
Completed NCT03415126 - A Study of ASN007 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02834052 - Pembrolizumab + Poly-ICLC in MRP Colon Cancer Phase 1/Phase 2
Not yet recruiting NCT06446557 - De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer Phase 3